Relmada Therapeutics Return on Equity

Relmada Therapeutics (RLMD) currently reports a ROE of -29.98%. That is below the Consumer Discretionary sector average of 22.95%. Use the charts on this page to explore Relmada Therapeutics's ROE history and peer comparisons.

Relmada Therapeutics's ROE of -29.98% is lower than the Consumer Discretionary sector average of 22.95%. That is roughly 230.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Relmada Therapeutics's current -29.98% should be judged against Consumer Discretionary norms (sector average: 22.95%) and against RLMD's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -29.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 22.95%. From there, open related valuation or income-statement pages for Relmada Therapeutics, and consider following RLMD for alerts when major investors trade the stock.

Relmada Therapeutics is classified in the Consumer Discretionary sector. On ROE, it currently shows -29.98% versus a sector average near 22.95%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing RLMD with unrelated industries.